Development and Testing of Transdermal Patches Containing Inclusion Complexed Repaglinide and Cyclodextrin

[摘要] Worldwide, chronic conditions like diabetes mellitus are very common. The goal of the study is to create a transdermal patch that may beapplied to the skin to treat diabetes while minimising the number of pills required and improving patient compliance. Repaglinide waschosen as the active ingredient for creating a transdermal patch based on the favourable findings of a feasibility study, which included adoctor's opinion and prescription survey. Repaglinide and cyclodextrin were complexed using the grinding process. In the currentinvestigation, several polymeric combinations, including Hydroxypropyl Methyl Cellulose (HPMC), Ethyl Cellulose (EC), and EudragitL100 with Poly Vinyl Pyrolidone (PVP), were used to develop Matrix-type transdermal patch systems containing repaglinide-cyclodextrincomplexes. The patches were subjected through physical-chemical tests, in vitro drug release experiments, and skin permeation tests [1].

[学科分类] 药理学